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Noncanonical GLI1 signaling promotes stemness features
and in vivo growth in lung adenocarcinoma
A Po1,10, M Silvano1,10, E Miele2,11, C Capalbo1, A Eramo3, V Salvati3, M Todaro4,5, ZM Besharat1, G Catanzaro6, D Cucchi1, S Coni1,
L Di Marcotullio1, G Canettieri1, A Vacca6, G Stassi4, E De Smaele6, M Tartaglia7, I Screpanti1,2, R De Maria3,8 and E Ferretti6,9
Aberrant Hedgehog/GLI signaling has been implicated in a diverse spectrum of human cancers, but its role in lung adenocarcinoma
(LAC) is still under debate. We show that the downstream effector of the Hedgehog pathway, GLI1, is expressed in 76% of LACs, but
in roughly half of these tumors, the canonical pathway activator, Smoothened, is expressed at low levels, possibly owing to
epigenetic silencing. In LAC cells including the cancer stem cell compartment, we show that GLI1 is activated noncanonically by
MAPK/ERK signaling. Different mechanisms can trigger the MAPK/ERK/GLI1 cascade including KRAS mutation and stimulation of
NRP2 by VEGF produced by the cancer cells themselves in an autocrine loop or by stromal cells as paracrine cross talk. Suppression
of GLI1, by silencing or drug-mediated, inhibits LAC cells proliferation, attenuates their stemness and increases their susceptibility to
apoptosis in vitro and in vivo. These ﬁndings provide insight into the growth of LACs and point to GLI1 as a downstream effector for
oncogenic pathways. Thus, strategies involving direct inhibition of GLI1 may be useful in the treatment of LACs.
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INTRODUCTION
The Hedgehog (HH)–GLI signaling is a conserved developmental
pathway whose physiological roles in mammals consist of
organogenesis, stem cell maintenance, and the upkeep and repair
of adult tissues.1 Core pathway components include the secreted
signaling proteins—Sonic HH (SHH), Indian HH or Desert
HH—which bind to and inactivate the transmembrane receptor
Patched (PTCH) on nearby target cells, annulling its repression of a
second transmembrane receptor, Smoothened (SMO). The com-
plex downstream signaling culminates in the expression of
glioma-associated oncogene (GLI)-family transcription factors
(GLI1, GLI2 and GLI3), whose targets comprise context-speciﬁc
genes that regulate differentiation, proliferation and survival. GLI
proteins also regulate the expression of genes encoding several
HH pathway components, including GLI1 itself and PTCH1,2
thereby creating positive and negative feedback loops.
Aberrant activation of the HH–GLI cascade can be caused by
a number of factors, including genetic alteration(s) involving
individual pathway components (for example, mutations affecting
PTCH or SMO,3 GLI1/2 ampliﬁcation4,5), and this anomalous
signaling activity has been implicated in the initiation, progression
and relapse of various types of cancer. In several epithelial forms
of cancer, the tumor cells are reportedly dependent on autocrine
HH–GLI stimulation.6 In other studies, however, HH-expressing
neoplastic epithelial cells appear to be unresponsive to the ligand
they produce, which acts instead on cells in the tumor stroma to
create a microenvironment favorable for tumor growth.6 Inap-
propriate HH–GLI signaling also plays critical roles in maintaining
the undifferentiated, self-renewing phenotype of the cancer stem
cell (CSC) populations in hematological malignancies and solid
tumors (including those of the lung, breast, pancreas, colon and
brain).7–11 These tumor-initiating subpopulations are considered
major drivers of tumor maintenance, metastasis, relapse and
resistance to chemotherapy.12,13 The HH–GLI pathway is thus an
intriguing potential target for novel therapies for these cancers.
Several small-molecule inhibitors have been developed that
suppress HH–GLI signaling via SMO blockade. Encouraging clinical
results have been achieved in patients with medulloblastoma or
basal cell carcinoma, which are associated with canonical HH–GLI
signaling activation.14 In contrast, treatment of colorectal, gastric
and ovarian cancers with these agents has not produced any
signiﬁcant responses.14 HH–GLI signaling is also known to play
crucial cell-intrinsic roles in the development and maintenance
of small-cell lung cancer.15 However, in patients with newly
diagnosed extensive-stage small-cell lung cancer, the addition of
SMO inhibition to standard chemotherapy regimens does not
appear to offer any beneﬁt in terms of progression-free or overall
survival.16
Similar pictures are emerging of non-small-cell lung cancers
(NSCLC), which account for approximately 85% of lung
malignancies.17 Several lines of evidence suggest that HH–GLI
signaling is a major player in NSCLC tumorigenesis and
maintenance. The two main NSCLC histotypes, adenocarcinomas
(LACs) and squamous cell carcinomas (LSCCs),18 express the GLI1
transcription activator19–22 as well as the HH ligand SHH.23 In both
histotypes, overexpression of HH–GLI pathway components has
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been linked to more aggressive behavior.21,22,24 Clinical trials are
underway on the use of SMO inhibitors in advanced solid tumors
including NSCLCs, but recently published preclinical data indicate
that these agents are likely to exert few if any antitumoral effects
on LSCC or LAC cells.24,25 Importantly, however, LSCC cell lines
that were unaffected by shRNA-mediated depletion of SMO
or its pharmacological inhibition responded to genetic and
pharmacological targeting of GLI with signiﬁcant decreases in
growth and markedly increased apoptosis.24 These ﬁndings are
consistent with the noncanonical, SMO-independent activation
of GLI-mediated transcription by input from other signaling
pathways26,27 such as the neuropilin-2/ERK (NRP2/ERK)
cascade,28 K-Ras/ERK signaling29 and the mTOR/S6K1 pathway.30
These considerations induced us to take a closer look at the
molecular mechanisms underlying HH–GLI pathway activation in
LACs and the role played by this pathway in LAC CSCs.
RESULTS
Expression of HH–GLI signaling pathway components in NSCLC
Interrogation of Oncomine31 microarray data sets on 1007 NSCLC
tissues revealed positive correlation between GLI1 and SMO mRNA
levels only in the LSCCs (Supplementary Figure S1a). Consistently,
immunohistochemistry (IHC) analyses of human NSCLC tissue
arrays disclosed GLI1 protein expression in most LACs (76%) and
LSCCs (60%), but over half the GLI1-positive LACs exhibited weak
SMO staining (Figures 1a and b). SHH was expressed in 28% of the
LSCCs and 35% of the LACs (Supplementary Figure S1b).
GLI1 and SMO expression were then assessed in commercial cell
lines and patient-derived CSC lines derived from NSCLCs (see
Supplementary Table S1 for genotypes).32,33 GLI1 was expressed in
all cell lines. SMO expression varied and was particularly low in
three LAC cell lines tested (H1437, CSC-3 and CSC-4—referred to
Figure 1. HH–GLI pathway components in NCSLC. (a, b) IHC of SMO and GLI1 protein expression in human NSCLC tissue arrays (216 LACs, 291
LSCCs): (a) distribution of SMO/GLI1 phenotypes and (b) representative images of GLI1 and SMO staining. The LSCC sample in (b) is positive
(H-score450/300) for both proteins; the LAC displays only GLI1 positivity. Magniﬁcation × 20, inset × 40. Scale bar: 50 μm. (c, d) Western blots
showing basal SMO and GLI1 protein expression in (c) commercial cell lines and (d) patient-derived CSCs from LSCC and LAC (see
Supplementary Table S1 for cell genotypes). Bar graphs show densitometrically quantiﬁed band intensity values (n= 3 or more) normalized to
actin (loading control, LC). Asterisks show differences vs cell line with highest SMO expression. (e, f) Methylation levels in the proximal SMO
regulatory region in (e) untreated LAC CSC lines and (f) commercial LAC cell lines before and after 5-AZA treatment. Cell lines are classiﬁed as
SMOhigh (SMOH) or SMOlow (SMOL) based on ﬁndings shown in panels c and d. (g, h) Effect of 5-AZA-mediated demethylation on SMO
expression (mRNA and protein) in (g) commercial LAC cell lines and (h) patient-derived LAC CSC lines. The mRNA level in each treated sample
was calibrated against the corresponding basal level. LC: GAPDH. Bar graphs: densitometric analyses. *Po0.05; **Po0.01; ***Po0.001
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hereafter as 'SMOlow cells'), as compared with both LSCC lines
tested (H520 and CSC-1) and with the remaining three LAC lines
('SMOhigh cells') (Figures 1c and d).
Aberrant methylation of the SMO promoter region in LAC
Re-interrogation of the Oncomine31 data sets revealed no NSCLC-
associated deletions/mutations involving the SMO region (chro-
mosome 7, band 7q32.1) that might explain the heterogeneous
expression documented in the LAC cell lines. To explore the
possibility that the low expression in H1437, CSC-3 and CSC-4
reﬂected epigenetic silencing of SMO, which has been described
in colorectal cancer,34,35 we interrogated the MethHC database.36
Compared with patient-matched normal lung (NL) tissue, LACs
(but not LSCCs) exhibited signiﬁcantly higher SMO promoter
methylation levels (Supplementary Figure S1c). Pyrosequencing
was then used to quantify DNA methylation at 42 CpG dinucleo-
tides in the SMO’s proximal regulatory region (Supplementary
Figures S1d and e). Methylation levels in SMOlow LAC cells (~50%
for CSC-4 and H1437) were signiﬁcantly higher than those
observed in SMOhigh cells (~5 for CSC-2, ~ 30% for H1734)
(Figures 1e and f and Supplementary Figure S1e). Treatment with
the demethylating agent 5-azacytidine (5-AZA) was followed by
signiﬁcantly reduced methylation levels and increased SMO
expression (mRNA and protein) in SMOlow cells, but it had no
effect on SMOhigh cells (Figures 1g and h).
Abrogation of SMO activity using shRNA-mediated knockdown
(shSMO) or the SMO antagonist vismodegib37 reduced GLI1
transcription and cell proliferation in SMOhigh cells but had
no effects in SMOlow cancer cells or in both SMOhigh and SMOlow
CSCs (Supplementary Figures S2a–h). The ineffectiveness
of SMO inhibition in LAC CSCs is consistent with previous
reports.25
To investigate SMO function further, we treated LAC cancer
cells with the SMO agonist purmorphamine.38,39 As shown in
Supplementary Figures S2i and j, purmorphamine produced
increases in GLI1 expression and cell viability in SMOhigh cells
but its effects in SMOlow cells were not signiﬁcant. When cells
were pretreated with 5-AZA, however, the effects of purmorpha-
mine on GLI1 levels and cell viability were signiﬁcant in the
SMOlow cancer cells (Supplementary Figures S2i and j). These
results indicate that SMO expression may be epigenetically
silenced in LAC cells, that in LAC CSCs regardless of SMO levels,
SMO inhibition is ineffective and that in LAC cancer cells SMO
retained mild functionality.
GLI1 inhibition reduces LAC cell survival and CSC stemness
features
Direct targeting of GLI1 activity had more substantial effects in
LAC cell lines and CSCs. Silencing of GLI1 signiﬁcantly reduced
viability in all lines tested (Figures 2a and b), and similar results
were achieved when the cells were treated with GANT61, whose
direct binding to GLI1 and GLI2 inhibits the latters’ DNA binding
and their transcriptional output.40,41 GANT61 is known to target
GLI1 speciﬁcally,42 and numerous groups have demonstrated its
high efﬁcacy against human cancer cells (reviewed in Gonnissen
et al.41). As shown in Figures 2c and d, GANT61 treatment
signiﬁcantly downregulated GLI1 levels in all LAC cell lines,
regardless of their SMO expression status, and this inhibition was
associated with signiﬁcantly diminished cell viability and
enhanced apoptosis (Supplementary Figure S3a).
Abrogation of GLI1 activity with shGLI1 or GANT61 treatment
also diminished the self-renewal capacity of LAC CSCs, as reﬂected
by their ability to form oncospheres (Figure 2e). Interestingly,
when shGLI1-transduced CSCs were treated with GANT61, no
additional decline was observed in the frequency of oncosphere-
forming cells (OFCs), which suggests that the drug’s effects in LAC
CSCs are mediated by its inhibition of GLI1. GANT61 treatment
also signiﬁcantly reduced the number of CSCs exhibiting high
aldehyde dehydrogenase activity (Figure 2f), which is an
established marker of lung CSCs.43,44 The drug also reduced the
expression of the lung CSC marker OCT4 (Figure 2g),32,45,46 and of
the ATP binding cassette transporter ABCG2 (Figure 2g), which is
commonly expressed by CSCs47,48 and interestingly enough is
reportedly regulated by HH pathway signaling.49–51
GLI1 inhibition reduces growth of LAC CSC-derived xenograft
tumors, attenuates their stemness and induces apoptosis
Having established that in vitro GLI1 inhibition with GANT61
reduces the stemness and survival capacity of LAC CSCs, we
investigated the drug’s in vivo effects on LAC CSC-derived
xenograft tumors (XTs) (Supplementary Figure S4a). Tumors in
GANT61-treated mice displayed signiﬁcantly slower growth than
their untreated counterparts (Figure 3a), together with decreased
transcription of GLI1 and PTCH1 (Figure 3b), downregulated
expression of OCT4 and ABCG2 (Figure 3c and Supplementary
Figure S4b), attenuated cell proliferation (Figure 3d) and increased
apoptosis (Figure 3e). As shown in Supplementary Figures S4c–e,
the features of GANT61-treated XTs were replicated in XTs
generated with LAC CSCs that had been stably infected with
shGLI1. Compared with vector-infected controls, shGLI1 XTs
exhibited slower growth (Supplementary Figure S4c), attenuated
stemness (Supplementary Figure S4d) and decreased cell pro-
liferation (Supplementary Figure S4e). These ﬁndings conﬁrm that
in vivo inhibition of GLI1 exerts antitumoral effects in LAC.
Noncanonical GLI1 activation in LAC
The results of the experiments described thus far indicate that a
substantial proportion of LACs are characterized by SMO-
independent, GLI-mediated transcription, a phenomenon pre-
viously documented in other cancers. GLI1 regulation has been
attributed to RAS/MEK signaling in breast cancer,28 melanoma52
and pancreatic ductal adenocarcinoma, and in the latter
tumors, GLI1 proved to be indispensable for KRAS-induced
carcinogenesis.53
Interestingly, in breast cancer, HH–GLI signaling was triggered
in an autocrine manner by stimulation of the VEGF receptor
neuropilin-2 (NRP2),28 whose expression in NSCLCs has been
linked to unfavorable outcomes.54–56 In its role as a VEGF receptor,
NRP2 speciﬁcally binds both VEGFA and VEGFC,57 and VEGF/NRP
signaling impacts the biology of stem-like tumor cells in various
types of cancer.58–60 We wondered whether oncogenic NRP2/ERK
signaling might be the upstream cause of the noncanonical GLI1
activity in LAC cells.
In support of this hypothesis, direct inhibition of MEK–ERK
cascade in these cells with U012661 signiﬁcantly reduced the
levels of GLI1 and inhibited the phosphorylation of the MEK
substrate ERK (Figures 4a and b). To determine whether the MEK–
ERK axis directly regulates Gli1 activity through its modiﬁcation,
we investigated GLI1 phosphorylation in LAC cells treated with the
selective MEK1/2 inhibitor U0126. As reported in Figure 4c, MEK
inhibition caused a reduction of phosphorylated GLI1, correspond-
ing to the active form of the transcription factor.30 Investigation of
the subcellular localization of phosphorylated GLI1 in LAC cells
showed positive nuclear staining for GLI1, which shifted to the
cytoplasm after U0126 treatment (Figure 4d). To study whether
ERK1 directly phosphorylates GLI1, we performed an in vitro kinase
assay using the puriﬁed recombinant fragment containing the
predicted ERK-sensing N-terminal region of GLI162 and ERK1. As
shown in Figure 4e, the results revealed direct phosphorylation of
GLI1, adding further support to the conclusion that MEK1–ERK1/2
activates GLI1 transcriptional activity in LAC cells.
Experiments designed to elucidate the upstream role of NRP2 in
the NRP2/ERK signaling showed that GLI1 expression was also
signiﬁcantly reduced in LAC cell lines after siRNA-mediated
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knockdown of NRP2 (Figure 5a). Similar decreases were seen in
LAC CSCs following shRNA NRP2 knockdown (Figure 5b). Of note,
NRP2 silencing was less effective in diminishing GLI1 expression
in CSC-2, which harbor the oncogenic KRASG12C mutation
(Supplementary Table S1 and Figures 5a and b).
As shown in Figure 5c, siNRP2 or siGLI1 in LAC cells both
produced signiﬁcant decreases in viability. In line with NRP2’s
putative role as an upstream activator of GLI1 in these cells, we did
not observe an additive effect when we combined NRP2 and GLI1
silencing.
To further clarify the role of KRAS mutation, we compared cell
viability in CSC-2 (KRASG12C mut) and CSC-4 (KRASwt). GLI1
knockdown diminished the viability on both CSC lines, whereas
shNRP2 decreased it only on CSC-4 (Figure 5d). No additive effects
were achieved with combined shNRP2 and shGLI1 depletion.
U0126-mediated inhibition of the MAPK/ERK/GLI1 signaling also
diminished the viability of LAC cell lines and CSCs. Similar effects
were achieved with direct targeting of GLI1 with GANT61, and no
additive effects were observed after their combination (Figures 5e
and f).
Finally, as shown in Supplementary Figure S5a, the GLI1-
modulating role of the NRP2/ERK axis was conﬁrmed by the
signiﬁcant upregulation in cells stimulated with recombinant
VEGF. Consistent with previous reports indicating that NRP2 and
VEGFA may be direct targets of GLI1,28 transcript levels of both the
receptor and its ligand in CSC-2 cells decreased signiﬁcantly after
siRNA-mediated GLI1 silencing (Supplementary Figure S5b).
Collectively, these ﬁndings support the existence of a self-
amplifying autocrine signaling loop in LAC cells where VEGF/
NRP2/MAPK/ERK signaling upregulates expression of GLI1 and
GLI1 in turn enhances the expression and function of NRP2
and VEGF.
Our next set of experiments sought to document the existence
of autocrine VEGF/NRP2/GLI1 signaling in vivo in LACs. Samples of
LAC CSC-derived XTs were analyzed with quantitative PCR using
assays speciﬁc for human transcripts to speciﬁcally characterize
pathway component expression patterns in the cancer-cell
compartments of tumors. Here we found NRP2 and VEGFA
transcripts levels that signiﬁcantly exceeded those found in
normal human lung tissue (NL) (Figures 6a and b). VEGFA was
previously shown to be often overexpressed in NSCLC.63 VEGFC
was expressed at very low levels so we did not investigate its role
further. Consistent with in vitro ﬁndings, XTs from GANT61-treated
mice displayed signiﬁcantly lower cancer-cell compartment
levels of NRP2 and VEGFA than those from control animals
(Supplementary Figure S6a).
The existence of an autocrine loop indicated by our in vitro
ﬁndings was supported by our in vivo data (Figures 4 and 5).
Figure 2. GLI1 inhibition diminishes proliferation and stemness in LAC cells. (a–d) LAC cells viability is diminished by GLI1 knockdown in
(a) commercial cell lines (siRNA-mediated) and (b) patient-derived CSCs (shRNA-mediated); similar reductions are seen in (c) cell lines and
(d) CSCs treated for 48 h with the GLI1 antagonist GANT61 or DMSO (− ). Bar graphs show viability (MTS assay); immunoblots show
endogenous GLI1 protein levels. LC: GAPDH. Numbers below blots indicate densitometrically quantiﬁed protein expression. (e) Effects of
GANT61 on oncosphere formation in LAC CSC lines before and after transduction with shGLI1. Bar graphs: frequencies of oncosphere-forming
cells (OFC, % of seeded cells that formed oncospheres) under indicated experimental conditions are normalized to the frequency observed in
shSCRAMBLE-infected cells treated with DMSO alone (controls, CTRL, expressed as 100%). Photomicrographs: Representative images of
oncospheres observed in DMSO-treated CSCs infected with shGLI1 or shSCRAMBLE (CTRL). Scale bar: 50 μm. (f) Percentage of CSCs exhibiting
high ALDH activity (ALDH+ cells) after GANT61 or CTRL treatment (AldeFluor assay). (g) Expression (mRNA and protein) of stem cell markers
OCT4 and ABCG2 in GANT61- and CTRL-treated (dashed line) CSCs. LC: GAPDH. *Po 0.05. ALDH, aldehyde dehydrogenase.
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Increasing evidence points to central roles for the tumor
stroma in cancer maintenance.64 In particular, in situ hybridiza-
tion studies have demonstrated the presence in LAC stroma
of HH pathway components.19 In addition, exogenous SHH
stimulation has been shown to activate canonical HH–GLI
signaling in normal lung ﬁbroblasts (LFs), upregulating their
secretion of various oncogenic factors, including VEGF.23 In all
the XTs we analyzed, SHH mRNA was highly expressed in the
cancer-cell compartments of the tumors (Figures 6c and d), but it
was undetectable in normal human lung (NL) and also in the XT
stroma. As shown in Figure 6e, exposure of murine LFs to
recombinant Shh markedly upregulated the transcription of Gli1
as well as that of VegfA. Analysis of the stromal compartment of
the LAC XTs revealed transcription of Smo (at levels resembling
those in normal murine lung and skin ﬁbroblasts (LF, SF)
(Supplementary Figure S6b), Gli1 (at levels signiﬁcantly higher
than those found in the normal ﬁbroblasts) (Figure 6f) and VegfA
(Figure 6g), and expression of the latter two genes was
signiﬁcantly downregulated in the stroma from GANT61-
treated mice. These data suggest a paracrine SHH-mediated
cross talk between the epithelial and stromal compartments of
the tumor,27 which activates canonical HH–GLI signaling in the
stroma, thereby upregulating the expression of VEGFA ligand
available for interaction with epithelial-cell NRP2.
Figure 3. GLI1 inhibition produces antitumor effects in LAC CSC-derived XTs. (a) Up: growth of XTs generated in mice by s.c. ﬂank injections of
LAC CSC-2 (XT-2), CSC-3 (XT-3) and CSC-4 (XT-4). Results are shown for 4 weeks of treatment with i.p. GANT61 or vehicle (CTRL). Bottom:
representative image of XTs after vehicle treatment of mice or after GANT61 treatment. Scale bar: 1 cm. (b) Human GLI1 and PTCH1 mRNA
levels in XTs from GANT61-treated and CTRL (dashed line) mice. (c) GANT61’s effects on endogenous GLI1, ABCG2 and OCT4 protein
expression in XTs. Bar graphs: densitometric analyses (see Supplementary Figure S3b for OCT4 IHC). (d, e) XT sections from GANT61-treated
and CTRL mice were (d) immunostained for the proliferation marker KI-67 and (e) subjected to TUNEL assay for apoptosis. Representative
results are shown (magniﬁcation: ×20; scale bar: 50 μm) with percentages of labeled cells (bar graphs on the right). Results are means± s.d.
(n= 3). *Po0.05, **Po0.01 versus CTRLs.
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Collectively, the above ﬁndings point to the existence in LACs of
a complex network in which GLI1 signaling can be activated by
autocrine stimulation, genetic alterations (for example, activating
KRAS mutations) and cross talk between the epithelial and stromal
compartments of the tumor (Figure 7).
DISCUSSION
LAC, the world’s leading cause of cancer-related death, is
characterized by high rates of somatic mutation and genomic
rearrangement.65 The most common genetic alteration involves
KRAS (33%). Aberrant signaling through several oncogenic path-
ways has also been described in LACs: that is, mitogen-activated
protein kinases (MAPK) activation (76%); phosphatidylinositol
3-kinases (PI3K)–AKT–mammalian target of rapamycin (mTOR)
activation (25%) and TP53 alteration (63%).65,66
Aberrant HH–GLI signaling has been implicated in the main-
tenance of various epithelial cancers, including those of
lung.14,19,39 In clinical trials, however, SMO inhibitors are produ-
cing disappointing results in several tumors.14,16 Recently it has
been shown that OFCs from LACs—unlike those from LSCCs—are
unresponsive to drug-mediated SMO inhibition and authors
Figure 4. MEK/ERK1/2 pathway regulates GLI1 phosphorylation. (a, b) Western blot analysis of endogenous levels of GLI1, phosphorylated
ERK1/2 (p-ERK1/2) and actin (LC) in commercial LAC cell lines (H1734, H1437) and CSCs 2, 3, 4 after 48 h U0126 treatments. Bar graphs:
densitometric analyses. Dashed line: CTRL treatment. *Po0.05; **Po0.01. (c) A549 and CSC-2 treated with U0126 for 4 h were lysed and
subjected to (left) IP—western blot assay to assess endogenous levels of phosphorylated GLI1 (p-GLI1). Right: WB analysis of input of samples
subjected to IP. (d) Immunoﬂuorescence assay of endogenous GLI1 expression in A549 after 12 h of U0126 treatment. Nuclei are
counterstained with Hoechst. Scale bars: 10 μm. (e) In vitro kinase assay. Recombinant GST-GLI1N (fragment 2-234) or GST were incubated with
or without recombinant ERK1 for 20 min. Phosphorylation was revealed by PAN anti-pSer immunoblot. Total levels of GST and GST-GLI1N,
revealed by α-GST immunoblot, are shown.
Noncanonical GLI1 activation in lung adenocarcinoma
A Po et al
4646
Oncogene (2017) 4641 – 4652
concluded that these cells are probably not dependent on HH–GLI
signaling.25 The LAC CSC we studied were also unaffected by SMO
inhibition, but our data indicate that their refractoriness is not a
reﬂection of HH–GLI signaling’s limited importance in these cells’
but rather of its noncanonical nature.
Our ﬁndings indicate that the canonical downstream effector of
the HH pathway, GLI1, is expressed by approximately 75% of all
LACs, but surprisingly, in roughly half of these GLI1-positive
tumors, key upstream activator of this pathway, SMO, is expressed
at low levels, at least in part owing to hypermethylation of its
promoter. Even in SMOlow cells, however, we found evidence of
GLI1-mediated transcription that was crucial for maintaining the
growth and stemness features of LACs. Although virtually
unaffected SMO targeting, this noncanonical HH–GLI signaling
could be signiﬁcantly impaired by GLI1 inhibition with antitumoral
effects in vitro as well as in vivo.
As illustrated in Figure 7, our data show that noncanonical
activation of GLI1 in LAC cells is at least partially the result of
oncogenic signaling through the MAPK/ERK pathway, a phenom-
enon that has been described in other types of cancer.28,29,52,53,67
One of the mechanisms underlying activation of the MAPK/ERK/
GLI1 cascade in LAC cells involves autocrine VEGFA stimulation of
NRP2 receptors expressed by epithelial tumor cells. Autocrine
VEGF/NRP2/GLI1 signaling has been implicated in the mainte-
nance of tumor-initiating cells in breast cancer28 and esophageal
adenocarcinoma.30 An autocrine loop involving NRP and VEGF has
also been described in skin cancer, where the expression of VEGFA
was shown to promote tumor growth not only by stimulating
angiogenesis within the stroma but also by enhancing stemness
features within the cancer-cell population.58
MAPK/ERK/GLI1 signaling can also be upregulated by paracrine
stimulation of the epithelial-cell NRP2 receptors by VEGFA
secreted by the stroma. This form of epithelial-cell/stromal-cell
cross talk is mediated by the expression and secretion of SHH by
the epithelial cells of LACs, which activates canonical HH–GLI
signaling in stromal cells, upregulating the transcription of VEGFA
and other GLI1 target genes.68–70 Our data build on and expands
evidence of a potential role in lung cancer of HH–GLI signaling in
the tumor stroma reported in earlier studies, where GLI1, SHH and
PTCH transcripts were documented in LAC stromal cells.19 Our
Figure 5. Noncanonical activation of GLI1 in LAC cells. (a, b) Western blots of endogenous protein levels of NRP2, GLI1 and P-ERK1/2 and actin
(LC) in commercial LAC cell lines (H1734, H1437) and CSCs 2, 3, 4 after siRNA-mediated (a) or short-hairpin-mediated (b) silencing of NRP2. Bar
graphs: densitometric analyses. Dashed line: CTRL treatment. (c–f) Cell viability (MTS assay) in (c) LAC cell lines after siRNA silencing of NRP2,
GLI1 and both; in (d) CSCs after short-hairpin mediated silencing of NRP2, GLI1 and both; and in (e) in LAC cell lines and (f) LAC CSCs treated
for 48 h with GANT61, U0126 or both. *Po0.05, **Po0.01 vs sham-treated/sham-transfected controls.
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data also extend observations by Bermudez et al.23 that SHH
secreted by lung cancer cells stimulates the proliferation of
ﬁbroblasts and their production of tumor-promoting factors,
including VEGF.
Genetically determined, constitutive activation of KRAS is a well-
known trigger of MAPK/ERK/GLI1 signaling.29 However, KRAS
mutation per se is not necessarily associated with oncogenic KRAS
activity.71 Functional comparison of various KRAS mutations in an
in vivo system of vertebrate tumorigenesis showed tumorigenic
effects for KRASG12C but not for KRASG13C.
72 These results are in
line with our ﬁnding that NRP2 silencing was less effective in
reducing viability in LAC cells harboring the KRASG12C mutation
than it was in KRASwt and KRASG13C cells.
KRAS mutation can also have important implications for
paracrine stimulation of NRP2/GLI signaling in LAC epithelial cells.
Mills et al.53 have shown that SHH secreted by pancreatic cancer
cells activates canonical HH–GLI signaling in stromal cells,
mediated in part by the upregulated expression of another GLI1
target gene. Interestingly, the expression of SHH by the cancer
cells was found to be regulated by KRAS. This mechanism could
parallel the role of stroma-produced VEGF as a target of SHH
induced GLI1 activation in stromal cells in our experiments.
Our results point to GLI1 as an important factor for maintaining
the biological aggressiveness of LACs, which is fully in line with
the results of a recent meta-analysis documenting the negative
prognostic repercussions of GLI1 expression in a wide range of
solid tumor types.73 In our model, the tumor-promoting effects of
GLI-mediated transcription are evident at multiple levels in LACs,
including CSC and non-CSC components of the cancer-cell
population and cells of the microenvironment that sustains them.
Unlike approaches that target upstream regulators of GLI1
signaling, direct abrogation of GLI1 activity itself can exert
antitumoral effects at all of these levels in LACs, in vitro and
in vivo. GANT61 has been intensively used in various cancer
research models; however, it has not been clinically tested.41
Other GLI antagonists, such as arsenic trioxide74 and atypical
protein kinase C antagonists,75 have been used in clinical settings,
but both require further investigation since they have molecular
targets other than GLI1. A more recently identiﬁed drug that
Figure 6. Autocrine GLI1 activation and paracrine HH–GLI signaling in LAC. (a, b) Cancer-cell component of XTs: basal mRNA levels of
(a) human NRP2 and (b) VEGFA vs levels in commercial normal human lung tissue (NL). Panel (a) shows IHC analysis of NRP2 expression in XT-3.
Magniﬁcation: × 20, scale bar: 50 μm. (c) Human SHH mRNA levels in the cancer-cell component of XTs 2, 3 and 4 and normal human lung
tissue (NL). (d) Representative IHC images of SHH and human nuclei (HuNu) staining in parafﬁn-embedded section of XT-3. Magniﬁcation:
× 20, scale bar: 50 μm. (e) Relative expression of Gli1 and VegfA mRNA in normal murine lung ﬁbroblasts (LF) treated for 24 h with recombinant
murine Shh or BSA alone (CTRL). Results are reported as means± s.d. (n= 4). (f, g) Stromal component of XTs 2–4 samples from GANT61-
treated and CTRL mice: mRNA levels of murine (f) Gli1 and (g) VegfA. Gli1 levels are expressed vs normal murine LFs. Values in a–d and f–g are
means± s.d. from four or more tumors. *Po0.05, **Po0.01, ***P40.001.
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speciﬁcally inhibits GLI1, glabrescione B,76 is now undergoing
preclinical investigation.
Prospective molecular proﬁling of LACs to assess their GLI1
status might be used to identify patients likely to beneﬁt from
GLI signaling blockade at different levels, with or without
conventional chemotherapy or other promising biological
approaches77,78
MATERIALS AND METHODS
All commercial products were used according to suppliers’ instructions
unless otherwise indicated.
Gene expression data set analyses
The Oncomine platform31 was used to interrogate data sets for LACs (Broet
Lung, Lee Lung and Weir Lung) and LSCCs (TCGA Lung, Bass Lung, Kuner
Lung, Larsen Lung and Lee Lung). Probes belonging to the same category
were pooled (700 samples for LACs, 347 for LSCCs). Pearson’s r and
correlation plots were generated to assess correlation between SMO and
GLI1 expression. The TCGA Lung 2 data set was interrogated for SMO
mutations in NSCLCs.
The MethHC database36 was interrogated to explore the methylation
status of SMO CpG islands in NSCLC.
Cell cultures
Cells. All cell lines were subjected to quality-control testing. NSCLC cell
lines A549, H1437 and H1734 were purchased from the ATCC (Milan, Italy);
H520 were provided by Prof. M Broggini. Patient-derived CSC lines were
obtained from primary LSCC (CSC-1) or LAC (CSC-2, -3 and -4). CSC-1–3
lines were characterized in Eramo et al.32 The CSC-4 line was isolated and
characterized with internal review board approval at the University of
Palermo. CSCs were maintained in advanced DMEM/F12 (Gibco Thermo
Fisher Scientiﬁc, Waltham, MA, USA) supplemented with N2 (Gibco Thermo
Fisher Scientiﬁc), B27 without vitamin A (Gibco Thermo Fisher Scientiﬁc),
and 50 μg/ml insulin (Sigma-Aldrich, Milan, Italy), 20 ng/ml EGF and 10 ng/
ml bFGF.
Murine lung and skin ﬁbroblasts were isolated from NOD/SCID/IL2Rγnull
mice as previously described.79
Treatments. Cells were treated (for 48 h unless otherwise speciﬁed)
with the following: 10 μM 5-AZA (Sigma-Aldrich); 20 μM GANT61 (ENZO
Lifesciences, Rome, Italy); 25 μM vismodegib (Selleckchem, Rome, Italy); 15 μM
Purmorphamine (Selleckchem), 10 μM U0126 (TocrisBioscience, Milan, Italy);
100 ng/ml Recombinant VEFG (R&D Systems, Minneapolis, MN, USA); 25 μg/
ml anti-VEGF (R&D Systems); and 3 μg/ml recombinant SHH (R&D Systems).
SiRNA-mediated silencing was performed with smart pool on-target plus GLI1
(ID: L-003896) and NRP2 (L-003896) (Dharmacon, Milan, Italy); non-target
siRNA was used as a control. For shRNA-mediated knockdown, PLKO lentiviral
particles carrying shRNA (Sigma-Aldrich): MISSION shRNA-non-target
control Transduction Particles (SCH002V) and three Lenti shGLI1: MISSION
shRNA Clone TRCN0000020485, TRCN0000020486 and TRCN0000020487.
Three lenti shSMO were used: MISSION shRNA Clone TRCN0000378375,
TRCN0000378354, TRCN0000358090; Clones TRCN0000020487 (shGLI1) and
TRCN0000358090 (shSMO) demonstrated the best knockdown efﬁciency with
less off target effect.
Assays. To assess self-renewal, CSCs were plated at clonal density in 96-
well plates. After 20 days the number of oncospheres was divided by the
number of cells plated to determine the OFC frequency. Cell viability was
assessed with MTS assay (Promega, Milan, Italy) and trypan blue exclusion.
Aldehyde dehydrogenase activity was quantiﬁed with Aldeﬂuor Kit (Stem
Cell Technologies, Meda MB, Italy). All experiments were performed in at
least three biological replicates.
Xenograft experiments
XTs were generated as previously described.32 CSCs (300 000 cells) were re-
suspended in 100 μl of culture medium and Matrigel (1:1) (BD Pharmingen,
Milan, Italy) and subcutaneously injected in the ﬂanks of 6-week-old female
NOD/SCID/IL2Rγnull mice (Charles River Laboratories, Calco, LC, Italy). Each
experimental group consisted of six mice, allocated using a simple
randomization method. Tumor volume (1/2(length×width2)) was assessed
using digital caliper. Mice were treated with GANT61 (40 mg/kg, i.p.)
re-suspended in ethanol and diluted to 100 μl per dose with 10%
(2-hydroxypropyl)-β-cyclodextrin (vehicle) or vehicle alone (controls).
Injections were administered twice a week for 4 weeks. All procedures
were performed with the approval of the Ethics Committee for Animal
Experimentation.
Immunohistochemistry
Standard-protocol IHC was done on Human Lung Cancer Survey tissue
microarrays (US Biomax, Milan, Italy) and formalin-ﬁxed parafﬁn-embedded
(FFPE) XT tissues. The UltraTek HRP Anti-Polyvalent (DAB) Staining System
(ScyTek, Logan, UT, USA) was used for blocking and detection; apoptosis
was detected with TUNEL-POD kit (Roche, Monza, Italy). Labeling was
detected with the UltraTek HRP Anti-Polyvalent (DAB) Staining System
(ScyTek). Stained sections were examined with a Leica DM1000 microscope
(Leica Microsystems Srl, Milan, Italy), photographed with a Jenoptik
ProgRes SpeedXT Core 3 camera (Jenoptik AG, Vienna, Austria), and
analyzed with ProgRes Capture Pro 2.8 software (Jenoptik AG).
Protein expression was evaluated with histoscore method (H-score):
staining intensity was rated from 0 (negative) to 3 (strong) for each sample
by two independent observers and the mean was used. H-score was
calculated multiplying the number of cells within each category in at least
three different × 200 ﬁelds. Human protein KI-67 expression and TUNEL
scores were reported as percentages of labeled cells with respect to
total cells.
Figure 7. Noncanonical GLI1 signaling sustaining LAC growth and
CSC maintenance. The HH pathway effector GLI1 can be activated
even in the absence of SMO, the canonical upstream activator of HH
signaling, whose expression is epigenetically silenced in many GLI1-
expressing LACs. GLI1 serves as a downstream effector of oncogenic
MAPK/ERK signaling, which can be triggered by ligand-binding
events at NRP2 receptors expressed by the cancer cells. GLI1 then
promotes features involved in tumor growth and CSC maintenance,
including the transcription of known HH target genes (for example,
ABCG2 and VEGFA). The VEGFA that binds epithelial-cell NRP2
receptors is secreted by the epithelial cells themselves, and this
autocrine signaling loop is self-ampliﬁed by GLI1-upregulated
transcription of both the receptor (NRP2) and its ligand (VEGFA).
NRP2/ERK/GLI signaling can also be activated in a paracrine fashion
by VEGFA secreted by cells in the tumor stroma. The stromal VEGFA
production is the result of canonical SMO-dependent HH–GLI
signaling triggered by SHH secreted by epithelial cells. The output
of this stromal signaling includes VEGFA, which in turn bind tumor-
cell NRP2, thereby triggering the noncanonical MAPK/ERK-mediated
GLI1 activation illustrated in the upper panel.
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Analysis of CpG island methylation status
DNA was extracted from LAC cells using Qiagen’s QIAamp DNA Mini Kit.
Methylation at the CpG islands in the SMO promoter was assessed by
pyrosequencing, performed according to standard procedures by Epi-
genDx Inc. (http://www.epigendx.com).
Western blotting
Western blots were performed according to standard procedures.80 Values
are expressed as band integrals normalized to the strongest band and on
the housekeeping gene.
Protein immunoprecipitation was performed as described in Canettieri
et al.,81 incubating 1.5 mg of each total protein extract with anti-Gli1 and
mouse IgG (Santa Cruz Biotechnology, Heidelberg, Germany), as a negative
control. Images were acquired using the BioRad ChemiDoc MP Imaging
System (BioRad, Hercules, CA, USA).
In vitro kinase assay
Recombinant GST-GLI1N (fragment 2-234 AA) and GST were produced
as described previously.81 The in vitro kinase assay was performed as
previously described.82 Recombinant ERK1 was purchased from Sigma-
Aldrich (E7407).
mRNA analysis
mRNA levels were analyzed as described in Po et al.7 Endogenous controls
were β-actin, GAPDH and HPRT for human samples, and Hprt1, β-2-
microglobulin and GusB for murine. NL RNA was purchased from Thermo-
Fisher Scientiﬁc (Waltham, MA, USA).
Immunoﬂuorescence
Immunoﬂuorescence was performed as described in Silvano et al.83 Images
were acquired with a Carl Zeiss microscope (Axio Observer Z1) and
AxioVision Digital Image Processing Software (Zeiss, Jena, Germany).
Antibodies
Santa Cruz Biotechnology: anti-SMO H-300 (sc-13943, IHC), anti-SMO N-19
(sc-6366, WB), anti-GLI1 H-300 (sc-20687, IHC), anti-actin I19 (sc-1616, WB),
anti-NRP2 (sc-13117, IHC and WB), anti-p-ERK1/2 (sc-101761, WB) and anti-
ABCG2 (sc-25821, WB). Abcam (Cambridge, UK): anti-SHH (ab53281, IHC),
anti-GAPDH (ab8245, WB) anti-OCT4 (ab19857, WB and IHC) and Phospho
—(Ser/Thr) (ab17464, WB-IP). Cell Signalling (Leiden, The Netherlands):
anti-GLI1 (L42B10, WB). Thermo Fisher Scientiﬁc: Anti-KI-67 (RM-9106, IHC).
EMD Millipore (Milan, Italy): Anti-human nuclei (MAB-1281, IHC) and anti-
phospho-serine (#16-455 Kinase assay).
Statistical analysis
Results are expressed as means± s.d. from an appropriate number of
experiments. Differences were analyzed by the Mann–Whitney U-test for
non-parametric values with similar variance using the GraphPad Prism
software Version 6.0 (La Jolla, CA, USA). Adjusted P-values of less than 0.05
were considered statistically signiﬁcant.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank Alberto Gulino, friend, mentor and colleague, who passed away while the
manuscript was in preparation, for his inspiring vision and continued support. This
work was supported by Associazione Italiana Ricerca Cancro (AIRC and AIRC
5XMILLE), Ministry of University and Research (FIRB, PRIN and PON), Sapienza
University of Rome (Ateneo), Pasteur Institute/Cenci Bolognetti Foundation, Umberto
Di Mario ONLUS Foundation, Italian Institute of Technology (IIT) projects. Medical
writing support was provided by ME Kent (EMWA) and funded by the Società Italiana
Articoli Laboratorio S.r.l (Rome, Italy).
AUTHOR CONTRIBUTIONS
Conceptualization: EF, AP and CC; methodology: AP, MS and EM; investigation:
AP, MS, EM, AE, VS, ZMB, MT, DC, GC, SC and LDiM; writing—original draft: AP,
EF and EDeS; writing—review and editing: EF, IS and GC; funding acquisition: EF
and EDeS and RDeM; resources: GS, MT and AE; supervision: EF.
REFERENCES
1 Lee RTH, Zhao Z, Ingham PW. Hedgehog signalling. Development 2016; 143:
367–372.
2 Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008; 22:
2454–2472.
3 Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis
induced by aberrant hedgehog signaling activation. Curr Mol Med 2009; 9:
873–886.
4 Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ et al. Identiﬁcation
of an ampliﬁed, highly expressed gene in a human glioma. Science 1987; 236:
70–73.
5 Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC et al. Rare
amplicons implicate frequent deregulation of cell fate speciﬁcation pathways in
oral squamous cell carcinoma. Oncogene 2005; 24: 4232–4242.
6 Theunissen J, de Sauvage F. Paracrine Hedgehog signaling in cancer. Cancer Res
2009; 69: 6007–6010.
7 Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G et al. Hedgehog
controls neural stem cells through p53-independent regulation of Nanog. EMBO J
2010; 29: 2646–2658.
8 Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-
GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol 2007; 17: 165–172.
9 Varnat F, Siegl‐Cachedenier I, Malerba M, Gervaz P, Ruiz i Altaba A. Loss of WNT‐
TCF addiction and enhancement of HH‐GLI1 signalling deﬁne the metastatic
transition of human colon carcinomas. EMBO Mol Med 2010; 2: 440–457.
10 Zbinden M, Duquet A, Lorente‐Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A.
NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐
functional network with GLI1 and p53. EMBO J 2010; 29: 2659–2674.
11 Justilien V, Fields A. Molecular pathways: novel approaches for improved ther-
apeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res
2015; 21: 505–513.
12 Garvalov B, Acker T. Cancer stem cells: a new framework for the design of tumor
therapies. J Mol Med 2011; 89: 95–107.
13 Matchett K, Lappin T. Concise reviews: cancer stem cells: from concept to cure.
Stem Cells 2014; 32: 2563–2570.
14 Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the
Hedgehog pathway in cancer. Nat Med 2013; 19: 1410–1422.
15 Park K, Martelotto L, Peifer M, Sos M, Karnezis A, Mahjoub M et al. A crucial
requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011; 17:
1504–1508.
16 Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N et al. Vismo-
degib or cixutumumab in combination with standard chemotherapy for patients
with extensive‐stage small cell lung cancer: a trial of the ECOG‐ACRIN Cancer
Research Group (E1508). Cancer 2016; 122: 2371–2378.
17 Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the man-
agement of lung cancer. J Thorac Dis 2013; 5: S463–S478.
18 Johnson D. Setting the bar for therapeutic trials in non-small-cell lung cancer:
how low can we go? J Clin Oncol 2014; 32: 1389–1391.
19 Singh S, Wang Z, Liang FD, Black K, Goetz J, Tokhunts R et al. Hedgehog-
producing cancer cells respond to and require autocrine Hedgehog activity.
Cancer Res 2011; 71: 4454–4463.
20 Raz G, Allen K, Kingsley C, Cherni I, Arora S, Watanabe A et al. Hedgehog signaling
pathway molecules and ALDH1A1 expression in early-stage non-small cell
lung cancer. Lung Cancer 2012; 76: 191–196.
21 Hwang J, Kang M, Yoo Y, Quan Y, Kim H, Oh S et al. The effects of sonic hedgehog
signaling pathway components on non-small-cell lung cancer progression and
clinical outcome. World J Surg Oncol 2014; 12: 268.
22 Yuan Z, Goetz J, Singh S, Ogden S, Petty W, Black C et al. Frequent requirement of
hedgehog signaling in non-small cell lung carcinoma. Oncogene 2007; 26: 1046–1055.
23 Bermudez O, Hennen E, Koch I, Lindner M, Eickelberg O. Gli1 mediates lung
cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell
activation. PLoS One 2013; 8: e63226.
24 Huang L, Walter V, Hayes DN, Onaitis M. Hedgehog–GLI signaling inhibition
suppresses tumor growth in squamous lung cancer. Clin Cancer Res 2014; 20:
1566–1575.
Noncanonical GLI1 activation in lung adenocarcinoma
A Po et al
4650
Oncogene (2017) 4641 – 4652
25 Justilien V, Walsh M, Ali S, Thompson E, Murray N, Fields A. The PRKCI and SOX2
oncogenes are coampliﬁed and cooperate to activate Hedgehog signaling in lung
squamous cell carcinoma. Cancer Cell 2014; 25: 139–151.
26 Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: impli-
cations for targeted anti-cancer therapy. Cell Cycle 2007; 6: 2458–2463.
27 Rubin L, de Sauvage F. Targeting the Hedgehog pathway in cancer. Nat Rev Drug
Discov 2006; 5: 1026–1033.
28 Goel H, Pursell B, Chang C, Shaw L, Mao J, Simin K et al. GLI1 regulates a novel
neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to
breast cancer initiation. EMBO Mol Med 2013; 5: 488–508.
29 Nolan-Stevaux O, Lau J, Truitt M, Chu G, Hebrok M, Fernandez-Zapico M et al. GLI1
is regulated through Smoothened-independent mechanisms in neoplastic pan-
creatic ducts and mediates PDAC cell survival and transformation. Genes Dev
2009; 23: 24–36.
30 Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY et al. The crosstalk of mTOR/S6K1
and Hedgehog pathways. Cancer Cell 2012; 21: 374–387.
31 Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B et al.
Oncomine 3.0: genes, pathways, and networks in a collection of 18 000 cancer
gene expression proﬁles. Neoplasia 2007; 9: 166–180.
32 Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identiﬁcation and
expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ
2008; 15: 504–514.
33 Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K et al. Tyr1068-
phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem
cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Cell
Death Dis 2015; 6: 1850.
34 Zhu Y, James R, Peter A, Lomas C, Cheung F, Harrison D et al. Functional
Smoothened is required for expression of GLI3 in colorectal carcinoma cells.
Cancer Lett 2004; 207: 205–214.
35 Kober P, Bujko M, Olędzki J, Tysarowski A, Siedlecki J. Methyl‐CpG binding col-
umn‐based identiﬁcation of nine genes hypermethylated in colorectal cancer. Mol
Carcinog 2011; 50: 846–856.
36 Huang W-Y, Hsu S-D, Huang H-Y, Sun Y-M, Chou C-H, Weng S-L et al. MethHC: a
database of DNA methylation and gene expression in human cancer. Nucleic Acids
Res 2014; 43: gku1151.
37 De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the
hedgehog pathway for the treatment of advanced cancers. Curr Opin Invest Drugs
2010; 11: 707–718.
38 Sinha S, Chen JK. Purmorphamine activates the Hedgehog pathway by targeting
Smoothened. Nat Chem Biol 2006; 2: 29.
39 Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Fei DL et al. The
hedgehog processing pathway is required for NSCLC growth and survival.
Oncogene 2013; 32: 2335–2345.
40 Lauth M, Bergström Å, Shimokawa T, Toftgård R. Inhibition of GLI-mediated
transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad
Sci USA 2007; 104: 8455–8460.
41 Gonnissen A, Isebaert S, Haustermans K. Targeting the hedgehog signaling
pathway in cancer: beyond smoothened. Oncotarget 2015; 6: 13899.
42 Agyeman A, Jha B, Mazumdar T, Houghton J. Mode and speciﬁcity of binding of
the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding.
Oncotarget 2014; 5: 4492.
43 Sullivan J, Spinola M, Dodge M, Raso M, Behrens C, Gao B et al. Aldehyde
dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on
notch signaling. Cancer Res 2010; 70: 9937–9948.
44 Jiang F, Qiu Q, Khanna A, Todd N, Deepak J, Xing L et al. Aldehyde dehydrogenase
1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7:
330–338.
45 Chen X, Fang F, Liou Y, Ng H. Zfp143 regulates Nanog through modulation of
Oct4 binding. Stem Cells 2008; 26: 2759–2767.
46 Chiou S, Wang M, Chou Y, Chen C, Hong C, Hsieh W et al. Coexpression of Oct4
and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer
stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer
Res 2010; 70: 10433–10444.
47 Fletcher J, Haber M, Henderson M, Norris M. ABC transporters in cancer: more
than just drug efﬂux pumps. Nat Rev Cancer 2010; 10: 147–156.
48 Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M, Colabufo N. ABC
transporters in CSCs membranes as a novel target for treating tumor relapse.
Front Pharmacol 2014; 5: 163.
49 Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F et al. ABCG2 is a
direct transcriptional target of hedgehog signaling and involved in stroma-
induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011; 30:
4874–4886.
50 Ingram W, Crowther L, Little E, Freeman R, Harliwong I, Veleva D et al. ABC
transporter activity linked to radiation resistance and molecular subtype in
pediatric medulloblastoma. Exp Hematol Oncol 2013; 2: 26.
51 Chen Y, Bieber M, Teng N. Hedgehog signaling regulates drug sensitivity by
targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol
Carcinog 2014; 53: 625–634.
52 Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V et al. Melanomas
require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the
RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007; 104: 5895–5900.
53 Mills L, Zhang Y, Marler R, Herreros-Villanueva M, Zhang L, Almada L et al. Loss of
the transcription factor GLI1 identiﬁes a signaling network in the tumor micro-
environment mediating KRAS oncogene-induced transformation. J Biol Chem
2013; 288: 11786–11794.
54 Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Abe Y et al. Neu-
ropilin 1 and neuropilin 2 co‐expression is signiﬁcantly correlated with increased
vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002; 95:
2196–2201.
55 Caunt M, Mak J, Liang W, Stawicki S, Pan Q, Tong R et al. Blocking neuropilin-2
function inhibits tumor cell metastasis. Cancer Cell 2008; 13: 331–342.
56 Nasarre P, Gemmill R, Potiron V, Roche J, Lu X, Barón A et al. Neuropilin-2 is
upregulated in lung cancer cells during TGF-β1–induced epithelial–mesenchymal
transition. Cancer Res 2013; 73: 7111–7121.
57 Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P et al. Neuropilin-2
interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell sur-
vival and migration. Blood 2006; 108: 1243–1250.
58 Beck B, Driessens G, Goossens S, Youssef K, Kuchnio A, Caauwe A et al. A vascular
niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.
Nature 2011; 478: 399–403.
59 Glinka Y, Mohammed N, Subramaniam V, Jothy S, Prud’homme G. Neuropilin-1 is
expressed by breast cancer stem-like cells and is linked to NF-κB activation and
tumor sphere formation. Biochem Biophys Res Commun 2012; 425: 775–780.
60 Hamerlik P, Lathia J, Rasmussen R, Wu Q, Bartkova J, Lee M et al. Autocrine VEGF–
VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and
tumor growth. J Exp Med 2012; 209: 507–520.
61 Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al.
Identiﬁcation of a novel inhibitor of mitogen-activated protein kinase kinase. J
Biol Chem 1998; 273: 18623–18632.
62 Riobo NA, Haines GM, Emerson CP. Protein kinase C-δ and mitogen-activated
protein/extracellular signal–regulated kinase-1 control GLI activation in Hedge-
hog signaling. Cancer Res 2006; 66: 839–845.
63 Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expres-
sion of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1
and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol
2003; 200: 336–347.
64 Kalluri R. The biology and function of ﬁbroblasts in cancer. Nat Rev Cancer 2016;
16: 582–598.
65 Network CGAR. Comprehensive molecular proﬁling of lung adenocarcinoma.
Nature 2014; 511: 543–550.
66 Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K et al. Somatic
mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:
1069–1075.
67 Seto M, Ohta M, Asaoka Y, Ikenoue T, Tada M, Miyabayashi K et al. Regulation of
the hedgehog signaling by the mitogen‐activated protein kinase cascade in
gastric cancer. Mol Carcinog 2009; 48: 703–712.
68 Cao X, Geradts J, Dewhirst M, Lo H. Upregulation of VEGF-A and CD24 gene
expression by the tGLI1 transcription factor contributes to the aggressive beha-
vior of breast cancer cells. Oncogene 2012; 31: 104–115.
69 Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F et al.
RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human
medulloblastoma. Proc Natl Acad Sci USA 2004; 101: 10833–10838.
70 Ingram W, Wicking C, Grimmond S, Forrest A, Wainwright B. Novel genes regu-
lated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene 2002; 21:
8196–8205.
71 Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. A gene
expression signature associated with 'K-Ras addiction' reveals regulators of EMT
and tumor cell survival. Cancer Cell 2009; 15: 489–500.
72 Park JT, Johnson N, Liu S, Levesque M, Wang YJ, Ho H et al. Differential in vivo
tumorigenicity of diverse KRAS mutations in vertebrate pancreas: a
comprehensive survey. Oncogene 2015; 34: 2801–2806.
73 Cheng J, Gao J, Tao K, Yu P. Prognostic role of Gli1 expression in solid malig-
nancies: a meta-analysis. Sci Rep 2016; 6: 22184.
74 Beauchamp E, Ringer L, Bulut G, Sajwan K, Hall M, Lee Y et al. Arsenic trioxide
inhibits human cancer cell growth and tumor development in mice by blocking
Hedgehog/GLI pathway. J Clin Invest 2011; 121: 148–160.
75 Atwood S, Li M, Lee A, Tang J, Oro A. GLI activation by atypical protein kinase C
[igr]/[lgr] regulates the growth of basal cell carcinomas. Nature 2013; 494:
484–488.
Noncanonical GLI1 activation in lung adenocarcinoma
A Po et al
4651
Oncogene (2017) 4641 – 4652
76 Infante P, Mori M, Alfonsi R, Ghirga F, Aiello F, Toscano S et al. Gli1/DNA inter-
action is a druggable target for Hedgehog‐dependent tumors. EMBO J 2015; 34:
200–217.
77 Thomas A, Liu S, Subramaniam D, Giaccone G. Reﬁning the treatment of NSCLC
according to histological and molecular subtypes. Nat Rev Clin Oncol 2015; 12:
511–526.
78 Pinato DJ, Shiner RJ, White SD, Black JR, Trivedi P, Stebbing J et al. Intra-tumoral
heterogeneity in the expression of programmed-death (PD) ligands in isogeneic
primary and metastatic lung cancer: implications for immunotherapy. OncoIm-
munology 2016; 5: e1213934.
79 Seluanov A, Vaidya A, Gorbunova V. Establishing primary adult ﬁbroblast cultures
from rodents. J Vis Exp 2010; 44: e2033.
80 Ronci M, Catanzaro G, Pieroni L, Po A, Besharat ZM, Greco V et al. Proteomic
analysis of human sonic hedgehog (SHH) medulloblastoma stem-like cells. Mol
Biosyst 2015; 11: 1603–1611.
81 Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P et al. Histone
deacetylase and Cullin3–RENKCTD11 ubiquitin ligase interplay regulates Hedge-
hog signalling through Gli acetylation. Nat Cell Biol 2010; 12: 132–142.
82 D’Amico D, Antonucci L, Di Magno L, Coni S, Sdruscia G, Macone A et al. Non-
canonical Hedgehog/AMPK-mediated control of polyamine metabolism supports
neuronal and medulloblastoma cell growth. Dev Cell 2015; 35: 21–35.
83 Silvano M, Miele E, Valerio M, Casadei L, Begalli F, Campese A et al. Consequences
of simulated microgravity in neural stem cells: biological effects and metabolic
response. J Stem Cell Res Ther 2015; 5: 2.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
Noncanonical GLI1 activation in lung adenocarcinoma
A Po et al
4652
Oncogene (2017) 4641 – 4652
